Send us a text

Surfing NASH extends its preview coverage of the upcoming EASL Congress with a three-part episode. This final conversation with Louise Campbell observes a paper she finds relevant to the recent NICE publishing of guidance around use of FibroScan in the primary care setting as well as International #NASHDay 2023. The presentation in reference is titled Patients with persistently abnormal liver biochemistry are under-investigated and can be rapidly identified using a novel case-finding database. Particularly, Louise notes that the paper is coming from the team of former podcast guest, Tim Jobson of Predictive Health Intelligence. The importance of being able to locate patients is underscored as critical in efforts to scan those with highest risk in the UK.

The world’s largest liver meeting takes place 21-24 June in Vienna with an international faculty of experts from over 200 institutions. The diverse program will feature 2500 abstracts and be a uniquely momentous occasion for developing multidisciplinary approaches aimed at putting a major dent in Fatty Liver disease. Stay tuned for more coverage and if you have any question or interests around the event, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected].

Today’s episode is sponsored by HistoIndex, the first global company to provide stain-free, fully automated imaging solutions for visualizing and quantifying morphological and architectural features of fibrosis. HistoIndex couples breakthrough biophotonic technology with an AI-powered digital pathology system to provide consistent, high-throughput imaging in liver disease and cancer. The platform benefits clinical research and speeds development of drugs and diagnostics. For more information, visit www.histoindex.com.

Stay Safe and Surf On!